AI-Driven Pathology and Blood-Based Biomarkers: A Golden Opportunity to Democratize Precision Oncology
Danh-Tai Hoang1, Tian-Gen Chang1, Cristina R Ferrone2
1Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Abstract:
Advancing global health equity requires a paradigm shift in precision oncology, which currently remains inaccessible to most patients worldwide because of the high cost and long turnaround time of sequencing-based biomarkers. Recent developments in artificial intelligence inference from routine histopathology slides and blood tests are now enabling rapid cost-effective prediction of survival of patients with cancer and treatment response in both developed and under-resourced regions globally.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Targeted Cancer Therapies
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
